EGFR TKI耐性のEGFR変異非小細胞肺がん（NSCLC）におけるHER3の標的化
Whitepaper
Clinical
抗体薬物複合体（ADC）や二重特異性抗体（bsAb）などの最近の技術的進歩により、HER3の標的化能力と薬理学的可能性が向上しました。
About the author
Domenique Catalano
Oncology Trialtrove Analyst | Citeline
Domenique Catalano is an Oncology Trialtrove Analyst involved in various data enhancements and projects supporting the Ask the Analyst service. She engages in trial landscape analyses and expert subject matter queries in oncology. With extensive primary and secondary research experience in the clinical trial and pharmaceutical industry, Domenique joined Trialtrove in 2023. A graduate of West Chester University in Pennsylvania, Domenique completed a dual major with a BS in both chemistry (pharmaceutical product development) and biology (cell & molecular concentration) and attained her MBA in 2023.
